Physician profile
Thomas S Smith
NPI 1275725426
$1,161.69
in general payments reported to CMS, 2019-2025
20 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.58 · 2024: $316 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $148.62 | 2024-2025 | |
| Lundbeck LLC | $147.49 | 2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $147.18 | 2024-2025 | |
| Ucb, INC. | $133.53 | 2024-2025 | Fintepla, Rystiggo, Zilbrysq |
| Abbvie INC. | $111.96 | 2021-2025 | |
| Argenx US, INC. | $78.37 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $59.05 | 2025 | Sunosi, Symbravo |
| Catalyst Pharmaceuticals, INC. | $44.40 | 2025 | |
| Mallinckrodt Hospital Products INC. | $39.74 | 2025 | Acthar |
| Csl Behring | $38.27 | 2025 | Hizentra |
| Eisai INC. | $37.56 | 2025 | |
| Lilly USA, LLC | $31.14 | 2024-2025 | Amyvid, Kisunla |
| Merz Pharmaceuticals, LLC | $28.04 | 2025 | Xeomin, Inbrija, Ampyra |
| Vanda Pharmaceuticals INC. | $27.33 | 2025 | Ponvory |
| Janssen Biotech, INC. | $19.30 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $17.41 | 2025 | Valtoco |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Pfizer INC. | $14.75 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.85 | 2024 | Rytary |
| Aucta Pharmaceuticals, INC. | $7.34 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.